Home/Bolden Therapeutics/Johnny Page, ScM

JP

Johnny Page, ScM

Co-Founder & CEO

Bolden Therapeutics

Therapeutic Areas

Neurology Psychiatry

Bolden Therapeutics Pipeline

Drug	Indication	Phase
Neurogenesis Platform	Multiple Neurological Disorders (Alzheimer's, Stroke, Depression, etc.)	Pre-clinical

Leadership Team at Bolden Therapeutics

Charles Polsky, MD

Executive Chairman

Anne Valat, PhD

Director of Research

Justin R. Fallon, PhD

Scientific Founder, SAB Chair

Ashley E. Webb, PhD

Scientific Founder, SAB Member

View full Bolden Therapeutics profile